| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
189,490,000 |
| Market
Cap: |
1.22(B) |
| Last
Volume: |
3,346,923 |
Avg
Vol: |
4,460,019 |
| 52
Week Range: |
$4.13 - $8.81 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 14 |
| Insider 6 Months : 14 |
| Insider 3/6 Months : 27.5 |
|
| Guru Rank Number : 455 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
153,240 |
153,240 |
153,240 |
153,240 |
| Total Buy Value |
$856,692 |
$856,692 |
$856,692 |
$856,692 |
| Total People Bought |
6 |
6 |
6 |
6 |
| Total Buy Transactions |
6 |
6 |
6 |
6 |
| Total Shares Sold |
0 |
0 |
16,866 |
495,199 |
| Total Sell Value |
$0 |
$0 |
$135,363 |
$5,999,241 |
| Total People Sold |
0 |
0 |
2 |
9 |
| Total Sell Transactions |
0 |
0 |
2 |
14 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Doyle Anthony |
Chief Financial Officer |
• • – |
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
34,000 |
235,401 |
|
- |
|
| Milano Vincent |
Director |
• • – |
2023-11-30 |
4 |
A |
$5.88 |
$5,621 |
D/D |
956 |
50,998 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2023-11-30 |
4 |
A |
$5.88 |
$5,621 |
D/D |
956 |
50,861 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2023-08-31 |
4 |
A |
$7.11 |
$5,624 |
D/D |
791 |
49,905 |
|
- |
|
| Milano Vincent |
Director |
• • – |
2023-08-31 |
4 |
A |
$7.11 |
$5,624 |
D/D |
791 |
50,042 |
|
- |
|
| Sanders Machelle |
Director |
• • – |
2023-06-15 |
4 |
S |
$7.98 |
$31,920 |
D/D |
(4,000) |
25,611 |
|
29% |
|
| Hutson Nancy J |
Director |
• • – |
2023-06-14 |
4 |
S |
$8.04 |
$103,443 |
D/D |
(12,866) |
81,818 |
|
27% |
|
| Lee Kenneth B Jr |
Director |
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,745 |
68,863 |
|
- |
|
| Mckee Amy E |
Director |
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,745 |
29,611 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,745 |
49,114 |
|
- |
|
| Abercrombie George B |
Director |
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,745 |
29,611 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2023-06-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
25,000 |
1,014,794 |
|
- |
|
| Sanders Machelle |
Director |
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,745 |
29,611 |
|
- |
|
| Aselage Steve |
Director |
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,745 |
63,339 |
|
- |
|
| Milano Vincent |
Director |
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,745 |
49,251 |
|
- |
|
| Galson Steven K |
Director |
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,745 |
29,611 |
|
- |
|
| Hutson Nancy J |
Director |
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,745 |
94,684 |
|
- |
|
| Levin Alan G |
Director |
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
16,745 |
37,090 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2023-05-31 |
4 |
A |
$8.27 |
$5,624 |
D/D |
680 |
32,369 |
|
- |
|
| Milano Vincent |
Director |
• • – |
2023-05-31 |
4 |
A |
$8.27 |
$5,624 |
D/D |
680 |
32,506 |
|
- |
|
| Levin Alan G |
Director |
• • – |
2023-05-31 |
4 |
A |
$8.27 |
$11,247 |
D/D |
1,360 |
20,345 |
|
- |
|
| Thackray Helen M. |
Chief R&D Officer |
• • – |
2023-04-03 |
4 |
AS |
$8.29 |
$58,030 |
D/D |
(7,000) |
207,275 |
|
-17% |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2023-03-21 |
4 |
OE |
$3.22 |
$99,997 |
D/D |
31,055 |
1,039,794 |
|
- |
|
| Levin Alan G |
Director |
• • – |
2023-02-28 |
4 |
A |
$8.85 |
$11,248 |
D/D |
1,271 |
18,985 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2023-02-28 |
4 |
A |
$8.85 |
$5,620 |
D/D |
635 |
31,689 |
|
- |
|
737 Records found
|
|
Page 2 of 30 |
|
|
0.29 (4.73%) 
